Advanced Search

Study Preview



Study Title and Description

Effects of term infant formulas containing high sn-2 palmitate with and without oligofructose on stool composition, stool characteristics, and bifidogenicity.



Key Questions Addressed
1 Is this an intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Effects of term infant formulas containing high sn-2 palmitate with and without oligofructose on stool composition, stool characteristics, and bifidogenicity.
Author Yao M., Lien EL., Capeding MR., Fitzgerald M., Ramanujam K., Yuhas R., Northington R., Lebumfacil J., Wang L., DeRusso PA.
Country *Research and Development, Nestlé Nutrition, King of Prussia, PA †Department of Food Science and Human Nutrition, University of Illinois, Urbana ‡Department of Pediatrics, Asian Hospital and Medical Center, Muntinlupa City, Philippines §Research and Development, Wyeth Nutritionals Ireland, Askeaton ||Medical Affairs Department, Wyeth Philippines Inc, Makati City, Philippines ¶Worldwide Research and Development, Pfizer Inc, Peapack, NJ #Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
Year 2014
Numbers Pubmed ID: 24840511

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber 4.1
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
pubyear 2014
  • Comments Comments (
    0
    ) |
country Philippines
  • Comments Comments (
    0
    ) |
design Randomized Controlled Trial (parallel)
  • Comments Comments (
    0
    ) |
blindness Double blind
  • Comments Comments (
    0
    ) |
diet Isocaloric/Maintenance
  • Comments Comments (
    0
    ) |
feedcontrol All food provided (metabolic study)
  • Comments Comments (
    0
    ) |
sampsize 375
  • Comments Comments (
    0
    ) |
runin No
  • Comments Comments (
    0
    ) |
washout Not applicable
  • Comments Comments (
    0
    ) |
dosechange No
  • Comments Comments (
    0
    ) |
age_adult
  • Comments Comments (
    0
    ) |
age_adol
  • Comments Comments (
    0
    ) |
age_child
  • Comments Comments (
    0
    ) |
age_baby
  • Comments Comments (
    0
    ) |
age_infant 1
  • Comments Comments (
    0
    ) |
age_oth
  • Comments Comments (
    0
    ) |
age_mean ~10.9 days
  • Comments Comments (
    0
    ) |
age_range < 1
  • Comments Comments (
    0
    ) |
bmi_mean NR
  • Comments Comments (
    0
    ) |
bmi_range NR
  • Comments Comments (
    0
    ) |
blhealth_healthy 1
  • Comments Comments (
    0
    ) |
blhealth_hyperlip
  • Comments Comments (
    0
    ) |
blhealth_diab
  • Comments Comments (
    0
    ) |
blhealth_hyperten
  • Comments Comments (
    0
    ) |
blhealth_digest
  • Comments Comments (
    0
    ) |
blhealth_met
  • Comments Comments (
    0
    ) |
blhealth_oth
  • Comments Comments (
    0
    ) |
blhealth_othspec
  • Comments Comments (
    0
    ) |
gender ~49
  • Comments Comments (
    0
    ) |
ftype1 Oligofructose
  • Comments Comments (
    0
    ) |
descrip1_1
  • Comments Comments (
    0
    ) |
descrip1_2
  • Comments Comments (
    0
    ) |
dose1_1 3 g/L
  • Comments Comments (
    0
    ) |
dose1_2
  • Comments Comments (
    0
    ) |
duration1 8 weeks
  • Comments Comments (
    0
    ) |
admin1 Powder
  • Comments Comments (
    0
    ) |
ftype2 Oligofructose
  • Comments Comments (
    0
    ) |
descrip2_1
  • Comments Comments (
    0
    ) |
descrip2_2
  • Comments Comments (
    0
    ) |
dose2_1 5 g/L
  • Comments Comments (
    0
    ) |
dose2_2
  • Comments Comments (
    0
    ) |
duration2 8 weeks
  • Comments Comments (
    0
    ) |
admin2 Powder
  • Comments Comments (
    0
    ) |
ftype3
  • Comments Comments (
    0
    ) |
descrip3_1
  • Comments Comments (
    0
    ) |
descrip3_2
  • Comments Comments (
    0
    ) |
dose3_1
  • Comments Comments (
    0
    ) |
dose3_2
  • Comments Comments (
    0
    ) |
duration3
  • Comments Comments (
    0
    ) |
admin3
  • Comments Comments (
    0
    ) |
ftype4
  • Comments Comments (
    0
    ) |
descrip4_1
  • Comments Comments (
    0
    ) |
descrip4_2
  • Comments Comments (
    0
    ) |
dose4_1
  • Comments Comments (
    0
    ) |
dose4_2
  • Comments Comments (
    0
    ) |
duration4
  • Comments Comments (
    0
    ) |
admin4
  • Comments Comments (
    0
    ) |
comparator1 control
  • Comments Comments (
    0
    ) |
cdose1 0
  • Comments Comments (
    0
    ) |
cduration1 8 weeks
  • Comments Comments (
    0
    ) |
cadmin1 Powder
  • Comments Comments (
    0
    ) |
comparator2 sn-2
  • Comments Comments (
    0
    ) |
cdose2 0
  • Comments Comments (
    0
    ) |
cduration2 8 weeks
  • Comments Comments (
    0
    ) |
cadmin2 Powder
  • Comments Comments (
    0
    ) |
comparator3 human milk
  • Comments Comments (
    0
    ) |
cdose3
  • Comments Comments (
    0
    ) |
cduration3 8 weeks
  • Comments Comments (
    0
    ) |
cadmin3 Diet
  • Comments Comments (
    0
    ) |
comparator4
  • Comments Comments (
    0
    ) |
cdose4
  • Comments Comments (
    0
    ) |
cduration4
  • Comments Comments (
    0
    ) |
cadmin4
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.